00:41 , Feb 9, 2018 |  BC Innovations  |  Product R&D

R is for readout

While AstraZeneca plc gets credit for transparency in publishing its metrics on R&D productivity, the data cover well-established targets addressed by conventional modalities. The more telling test for its “5R framework” will be whether it...
08:00 , Feb 25, 2016 |  BC Innovations  |  Distillery Techniques

Techniques: In vivo reprogramming of stomach cells into insulin-secreting pancreatic β-like cells

Drug platforms TECHNOLOGY: Cell therapy Insulin-secreting pancreatic β-like cells derived from renewable stomach cells could help treat diabetes. In mice, gastrointestinal and antral stomach enteroendocrine cells were engineered to express three human genes - neurogenin...
08:00 , Jan 29, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: 5-lipoxygenase activating protein (FLAP; ALOX5AP)

Inflammation INDICATION: Inflammation Studies in vitro and in whole blood identified a new FLAP inhibitor that could help treat inflammation. Chemical synthesis and in vitro screening identified a lead compound called AZD6642 that inhibited FLAP...
07:00 , May 22, 2014 |  BC Innovations  |  Tools & Techniques

A big heart

Cell therapies in the clinic for heart failure draw from divergent sources of nonembryonic stem cells but have shown only minimal improvements in cardiac function. A University of Washington team thinks human embryonic stem cell-derived...
08:00 , Nov 25, 2013 |  BC Week In Review  |  Clinical News

TissuGlu Surgical Adhesive regulatory update

Cohera submitted the fourth and final module of a PMA to FDA for TissuGlu Surgical Adhesive for fluid management during large flap surgeries, such as abdominoplasty. The fourth module contains data from a pivotal trial...
07:00 , Sep 12, 2011 |  BC Week In Review  |  Company News

Amira, Bristol-Myers deal

Amira Pharmaceuticals Inc. , San Diego, Calif.   Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y.   Business: Pulmonary, Neurology, Cancer   Bristol-Myers completed its acquisition of Amira for $325 million in cash, plus up to...
00:11 , Sep 10, 2011 |  BC Extra  |  Company News

Bristol-Myers spins out Amira assets

Bristol-Myers Squibb Co. (NYSE:BMY) created two newcos with assets from recently acquired inflammation company Amira Pharmaceuticals Inc. The first, Panmira Pharmaceuticals LLC (San Diego, Calif.), received Amira's prostaglandin D2 (PGD2) receptor ( CRTH2 ; GPR44...
07:00 , Aug 1, 2011 |  BioCentury  |  Strategy

Therapeutically adjacent

Bristol-Myers Squibb Co. 's acquisition of Amira Pharmaceuticals Inc. appears at first blush to net a single compound that has completed Phase I testing in a completely new disease area for the pharma, along with...
07:00 , Jul 25, 2011 |  BC Week In Review  |  Company News

Amira, Bristol-Myers deal

Bristol-Myers will acquire Amira for $325 million in cash, plus up to $150 million in milestones. Bristol-Myers will gain Amira's AM152 , an oral lysophosphatidic acid receptor 1 ( LPA1 ) antagonist that has completed...
08:00 , Feb 10, 2011 |  BC Innovations  |  Targets & Mechanisms

Getting a GRP on asthma

Researchers at the Duke University School of Medicine have shown that...